Announced Thu, 9 Jul · 11:06 IST
Routine SEBI Regulation 74(5) compliance certificate filed for Q1 FY27
Compliance View source PDF
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹86.50
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+0.1+4.0+4.2+0.3+0.6+3.3————
Up moveDown movePending
AI summary
Indo US Bio-Tech filed a routine SEBI Regulation 74(5) certificate for the quarter ended June 30, 2026. The company's Registrar, Bigshare Services, confirmed no securities were received from depository participants for dematerialization during the quarter. Consequently, no share certificates were cancelled or substituted in the register of members. This is a standard quarterly procedural compliance requirement with no operational change.
Likely market impact
Purely procedural compliance filing. No impact on shareholders, shareholding, or stock price.